资讯

BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...
BACKGROUND: Fontan circulatory failure (FCF) is a chronic state in palliated single ventricle heart disease with high morbidity and mortality rates, including heart failure, multisystem end-organ ...
BACKGROUND: Evaluation of whether dyspnea has a cardiac cause is essential. Guidelines from 2016 were reported to result in a ...
Cardiovascular disease (CVD) is the predominant cause of death globally, accounting for ≈30% of deaths each year. 1 The prevalence of CVD among adults (aged ≥20 years) in the United States was 48.6% ...
BACKGROUND: Clinical guidelines recommend different revascularization strategies for nonculprit lesions in patients with ST-segment–elevation myocardial infarction (STEMI) versus non-STEMI (NSTEMI).
Circulation: Arrhythmia and Electrophysiology A specialized journal dedicated to advancing the understanding and management of cardiac arrhythmias and electrophysiology Editor-in-Chief: Paul J. Wang, ...
Intraoperative transesophageal echocardiography is used with increasing frequency in cardiac surgery for monitoring and diagnostic purposes. Recent data have shown the impact of improved outcomes in ...
Intracranial arterial dolichoectasia (IADE) is associated with cerebral small vessel disease (CSVD) in populations with ischemic stroke. Whether IADE is related to CSVD markers in patients with ...
Acute fulminant myocarditis (AFM) is characterized by sudden, severe cardiac inflammation causing hemodynamic instability or arrhythmia. 1 Currently, no approved medical therapy exists for AFM. Janus ...
BACKGROUND: Indirect and direct approaches to assess sympathetic cardiovascular drive have shown that patients with essential hypertension responsive to the blood pressure–lowering effects of ...
Open in Viewer Figure. Illustrations, examples, and overview of analytical tools for assessing third variables in epidemiological studies and secondary analyses of randomized clinical trials. Third ...